Elamipretide

Elamipretide, sold under the brand name Forzinity, is a medication used for the treatment of Barth syndrome. Elamipretide is a mitochondrial cardiolipin binder. It is used as the hydrochloride salt. It is given by injection under the skin (subcutaneous).

The most common side effects identified in clinical trials include mild-to-moderate injection site reactions.

Elamipretide was approved for medical use in the United States in September 2025. The US Food and Drug Administration considers it to be a first-in-class medication.